Literature DB >> 3893440

Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.

J G Cory, G L Carter, P E Bacon, A T'ang, E J Lien.   

Abstract

A series of N-hydroxy-N'-aminoguanidine derivatives was studied for their effects on L1210 cell growth and ribonucleotide reductase activity. With the twelve compounds studied, there was a good correlation between the inhibition of L1210 cell growth and the inhibition of ribonucleotide reductase activity. The most potent compound required concentrations of only 1.4 and 2 microM for 50% inhibition of L1210 cell growth and ribonucleotide reductase activity respectively. These guanidine analogs specifically inhibited the conversion of [14C]cytidine and deoxycytidine nucleotides in the nucleotide pool and the incorporation of [14C]cytidine into DNA without altering the incorporation of [14C]cytidine into RNA. Ribonucleotide reductase activity in drug-treated cells was reduced markedly. Iron-chelating agents did not either increase or decrease the inhibition caused by the N-hydroxy-N'-aminoguanidine derivatives. No evidence was obtained that these derivatives selectively inactivated one of the subunits of ribonucleotide reductase. These compounds appear to inhibit ribonucleotide reductase by a mechanism different from hydroxyurea or the thiosemicarbazone derivatives.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893440     DOI: 10.1016/0006-2952(85)90561-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Quantitative structure-activity relationship (QSAR) analysis of the cytotoxicities of aminohydroxyguanidine derivatives and their antiviral activities in vitro.

Authors:  P H Wang; M B Hui; P Nandy; S Banerjee; H Gao; E J Lien
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

2.  Nitric oxide involvement in the toxicity of hydroxyguanidine in leukaemia HL60 cells.

Authors:  S A Everett; K A Smith; K B Patel; M F Dennis; M R Stratford; P Wardman
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.

Authors:  M Matsumoto; T Tihan; J G Cory
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C).

Authors:  P B Koneru; E J Lien; V I Avramis
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

5.  Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.

Authors:  M Matsumoto; J G Fox; P H Wang; P B Koneru; E J Lien; J G Cory
Journal:  Biochem Pharmacol       Date:  1990-10-15       Impact factor: 5.858

6.  Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate.

Authors:  A Das; M D Trousdale; S Ren; E J Lien
Journal:  Antiviral Res       Date:  1999-12-31       Impact factor: 5.970

7.  Inhibition of human adenoviruses by 1-(2'-hydroxy-5'-methoxybenzylidene)amino-3-hydroxyguanidine tosylate.

Authors:  M B Hui; E J Lien; M D Trousdale
Journal:  Antiviral Res       Date:  1994-08       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.